Circadian Rhythm as a Therapeutic Target for Perioperative Cardioprotection
Circadian Rhythm as a Therapeutic Target for Perioperative Cardioprotection
批准号:
10659089
负责人:
Holger K. Eltzschig
金额:
$66.0万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-05-11 至 2027-04-30
关键词:
3-DimensionalAREG geneARNTL geneAddressAmino AcidsAmphiregulinAnticoagulationApplications GrantsAreaBindingBiochemicalBiopsyCardiac Surgery proceduresCircadian RhythmsClinicalCo-ImmunoprecipitationsComplexCritical CareCryoelectron MicroscopyDNADataExposure toGenesGenetic TranscriptionGenetic studyGoalsHemorrhageHeterodimerizationHourHypoxiaIn SituIn VitroInfarctionInjuryInterventionLeftLeft ventricular structureLinkMapsMass Spectrum AnalysisMediatingMedicineModelingMorbidity - disease rateMusMuscle CellsMyocardial IschemiaMyocardial ReperfusionMyocardial Reperfusion InjuryMyocardiumMyosin ATPaseOperative Surgical ProceduresOutcomePathway interactionsPatient-Focused OutcomesPatientsPatternPeriodicityPerioperativePharmacology StudyPlatelet InhibitorsPreventionProspective StudiesProteinsRegulationResearch ProposalsResistanceResolutionResponse ElementsRetrospective StudiesRiskRoleSeveritiesSignal TransductionSiteStructureTherapeutic InterventionTimeTransgenic MiceVariantVentricularaortic valve replacementbHLH-PAS factor HLFbiophysical analysiscardioprotectioncircadiandifferential expressionelectron densityin vivomortalitymouse modelmyocardial injurynovelnovel strategiesnovel therapeutic interventionorgan injurypercutaneous coronary interventionpharmacologicpreventpromoterprotective pathwayrandomized, clinical trialstargeted treatmenttherapeutic targettranscription factortranscriptome sequencingtreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The main goal of this grant application is to target circadian rhythm for perioperative cardioprotection.
Perioperative myocardial ischemia-reperfusion injury (IRI) and infarction continue to be major causes of morbidity
and mortality in surgical patients. However, percutaneous coronary intervention in combination with
anticoagulation and platelet inhibitors may be unsuitable in the perioperative setting due to the risk of bleeding
from the surgical site. Finding novel pharmacologic or interventional strategies to render the myocardium more
resistant to the deleterious effects of myocardial IRI would be highly significant for perioperative and critical care
medicine. Previous studies indicate that the occurrence of myocardial IRI follows a circadian pattern which could
be linked to an interaction between circadian rhythm and hypoxia signaling. Thus, the current application is
focused on identifying circadian mechanisms that could be targeted therapeutically to dampen myocardial IRI.
To study the circadian control of myocardial IRI, we established a murine model of in situ myocardial IRI and
found the smallest infarct sizes at zeitgeber time (ZT) 8 (3 pm), and largest infarct sizes at ZT 20 (3 am).
Subsequent unbiased RNA sequencing of the area at risk from the left ventricle of mice exposed to myocardial
IRI at ZT8 versus ZT20 pointed us toward the core circadian transcription factor - Bmal1. Similarly, RNA-seq
data from left ventricular biopsies of patients undergoing cardiac surgery in the morning versus afternoon groups
confirmed BMAL1 as the most differentially expressed gene. In functional studies, using transgenic mice with
myocyte-specific deletion of Bmal1 (Bmal1loxp/loxp Myosin Cre+ mice), we observed complete blunting of the
cardioprotective effect at ZT8. Co-immunoprecipitation followed by mass spectrometry identified hypoxia-
inducible factor 2-alpha (HIF2A) as a binding partner for BMAL1. Similar to Bmal1loxp/loxp Myosin Cre+ mice, we
observed abolished cardioprotection at ZT8 in Hif2aloxp/loxp Myosin Cre+ mice. Subsequent biochemical and
biophysical studies revealed a direct interaction between BMAL1 and HIF2A showing a 4.5 Å electron density
map of the BMAL1/HIF2A heterodimer in complex with hypoxia-response element (HRE) DNA. Finally, we
identified amphiregulin (AREG) as a critical transcriptional co-target for BMAL1/HIF2A heterodimer in mediating
circadian-dependent cardioprotection. Thus, we hypothesize that BMAL1 and HIF2A form a transcriptionally
active complex critical in mediating circadian-dependent cardioprotection via daytime-dependent
regulation of AREG. We propose three Specific Aims to address this hypothesis: (1) Characterize the interaction
between BMAL1 and HIF2A and their functional roles during hypoxia in vitro or myocardial IRI in vivo. (2) Study
the co-target gene of BMAL1/HIF2A – AREG in mediating circadian-dependent cardioprotection. (3) Target
BMAL1/HIF2A for cardioprotection and proof-of-principle studies during perioperative myocardial IRI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functional Role of HIF-PHDs in ARDS
-
批准号:10718267
-
项目类别:
-
资助金额:$70.93万
-
财政年份:2023
-
负责人:Holger K. Eltzschig
-
依托单位:
Research Training of Anesthesiology Physician-Scientists
-
批准号:10618804
-
项目类别:
-
资助金额:$26.12万
-
财政年份:2022
-
负责人:Holger K. Eltzschig
-
依托单位:
Research Training of Anesthesiology Physician-Scientists
-
批准号:10333808
-
项目类别:
-
资助金额:$16.64万
-
财政年份:2022
-
负责人:Holger K. Eltzschig
-
依托单位:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
-
批准号:10598586
-
项目类别:
-
资助金额:$44.51万
-
财政年份:2020
-
负责人:Holger K. Eltzschig
-
依托单位:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
-
批准号:10366015
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2020
-
负责人:Holger K. Eltzschig
-
依托单位:
microRNA miR-147 Dampens Alveolar Epithelial Inflammation During ARDS
-
批准号:10316251
-
项目类别:
-
资助金额:$45.88万
-
财政年份:2020
-
负责人:Holger K. Eltzschig
-
依托单位:
microRNA miR-147 Dampens Alveolar Epithelial Inflammation During ARDS
-
批准号:10535454
-
项目类别:
-
资助金额:$46.19万
-
财政年份:2020
-
负责人:Holger K. Eltzschig
-
依托单位:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
-
批准号:9980672
-
项目类别:
-
资助金额:$47.76万
-
财政年份:2020
-
负责人:Holger K. Eltzschig
-
依托单位:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
-
批准号:10162584
-
项目类别:
-
资助金额:$45.66万
-
财政年份:2020
-
负责人:Holger K. Eltzschig
-
依托单位:
MicroRNA Shuttling during Acute Respiratory Distress Syndrome
-
批准号:9311720
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2017
-
负责人:Holger K. Eltzschig
-
依托单位:
MicroRNA Shuttling during Acute Respiratory Distress Syndrome
-
批准号:9902508
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2017
-
负责人:Holger K. Eltzschig
-
依托单位:
Proton Pump Inhibitors for Perioperative Acute Kidney Injury
-
批准号:9395979
-
项目类别:
-
资助金额:$33.5万
-
财政年份:2016
-
负责人:Holger K. Eltzschig
-
依托单位:
Proton Pump Inhibitors for Perioperative Acute Kidney Injury
-
批准号:9384234
-
项目类别:
-
资助金额:$10.59万
-
财政年份:2016
-
负责人:Holger K. Eltzschig
-
依托单位:
Amphiregulin Signaling in Perioperative Cardio-Protection
-
批准号:9381517
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2016
-
负责人:Holger K. Eltzschig
-
依托单位:
Amphiregulin Signaling in Perioperative Cardio-Protection
-
批准号:8697792
-
项目类别:
-
资助金额:$38.72万
-
财政年份:2014
-
负责人:Holger K. Eltzschig
-
依托单位:
Amphiregulin Signaling in Perioperative Cardio-Protection
-
批准号:8824560
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2014
-
负责人:Holger K. Eltzschig
-
依托单位:
Amphiregulin Signaling in Perioperative Cardio-Protection
-
批准号:9012107
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2014
-
负责人:Holger K. Eltzschig
-
依托单位:
Proton Pump Inhibitors for Perioperative Acute Kidney Injury
-
批准号:8830972
-
项目类别:
-
资助金额:$33.54万
-
财政年份:2013
-
负责人:Holger K. Eltzschig
-
依托单位:
Proton Pump Inhibitors for Perioperative Acute Kidney Injury
-
批准号:8641353
-
项目类别:
-
资助金额:$33.67万
-
财政年份:2013
-
负责人:Holger K. Eltzschig
-
依托单位:
Proton Pump Inhibitors for Perioperative Acute Kidney Injury
-
批准号:8506884
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2013
-
负责人:Holger K. Eltzschig
-
依托单位: